Opinions The Panic-Proof Portfolio (Stockchase Research)
Teva PharmaceuticalTEVATOP PICKSep 29, 2026
Stock price when the opinion was issued
As of Oct 01, 2026. Market Open.
You might be interested:
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPremium contentMoody's just upgraded the credit rating to investment grade citing "the ongoing success of Teva’s growth strategy, including its key innovative products, an expanded pipeline and continued debt reduction supported by earnings growth. Moody’s also noted Teva’s revenue diversity, improving operating margins, solid free cash flow and ample cash on hand, as well as its expectation that Teva will further reduce debt over the next 12 to 18 months." Cash reserves are growing, while debt is reduced. We recommend setting a stop-loss at $30, looking to achieve $44 -- upside potential of 18%. Yield 0%
(Analysts’ price target is $42.38)(Note the short timeframe.) Healthcare and drug sectors have been strong, so this should have done better. Reasonably high in the RSI index, it's OK, he still owns.
Colin CieszynskiThe demand of GLP remains strong, but as more generics enter the market, the prices of the GLPs will go down. If you bet on Teva, you expects GLP demand to remain strong. GLP will come in pill shape, and there will be more amazing drug discoveries. However, Teva isn't a very innovative company. He avoids pharma; it's too hard to determine who will be a winner.
HQ is in Israel. Large-cap pharma. Right now, #1-ranked in his ADR/CDR universe (international stocks with American/Canadian Depositary Receipts). We've seen rotation into drug stocks. Broke out over $21 in September and has kept right on going. Very strong accumulation for about 6 months now. No dividend.
(Analysts’ price target is $34.50)Colin Cieszynski
We reiterate this pharma company as a TOP PICK. It trades at 20x earnings, 12x if you include analyst EPS growth projections of 40% next year, and supports a 32% ROE. We like that cash reserves are growing, while debt is aggressively retired and shares bought back. We continue to recommend a stop at $33, looking to achieve $47 -- upside potential of 18%. Yield 0%
(Analysts’ price target is $43.73)